Abstract: Multiple myeloma(MM)is a hematological malignancy.The treatment of multiple myeloma has undergone significant developments in recent years.The availability of the novel agents induding thalidomide,bortezomib,and lenalidomide has expanded treatment options and improved the outcome of patients with MM.A number of phase III trials have demonstrated the efficacy of novel agent combinations in the transplant and nontransplant settings.Based on these results,standard induction regimens are being challenged and replaced.In the transplant setting,a number of newer induction regimens are now available.It has been shown to be superior to the vincristine,doxorubicin,and dexamethasone(VAD)regimen.Similarly,in the front-line treatment of patients not eligible for transplantation,regimens incorporating novel agents have been found to be superior to the traditional melphalan plus prednisone(MP)regimen.The advance of therapy of multiple myeloma based on the combination of the novel agents treatment strategies are reviewed.